Increased Spironolactone Dosing in Acute Heart Failure Alters Potassium Homeostasis but Does not Enhance Decongestion
Journal of Cardiac Failure · 2024-11 · 30 (11) · 1522-1526
DOI: 10.1016/j.cardfail.2024.06.008 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cardiac Failure, 2024-11. Verfasst von Peter S Natov und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA. Hauptthemen laut MEDLINE: Spironolactone, Heart Failure, Potassium, Mineralocorticoid Receptor Antagonists. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 8 Literaturangaben.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
BACKGROUND: The ATHENA-HF (Aldosterone Targeted Neurohormonal Combined with Natriuresis Therapy in Heart Failure) clinical trial found no improvements in natriuretic peptide levels or clinical congestion when spironolactone 100 mg/day for 96 hours was used in addition to usual treatment for acute heart failure. METHODS: We performed a post hoc analysis of ATHENA-HF to determine whether spironolactone treatment induced any detectable pharmacodynamic effects and whether patients with potentially greater aldosterone activity experienced additional decongestion. Trial subjects previously treated with spironolactone were excluded. We first examined for changes in renal potassium handling. Using the baseline serum potassium level as a surrogate marker of spironolactone activity, we then divided each treatment arm into tertiles of baseline serum potassium and explored for differences in laboratory and clinical congestion outcomes. RESULTS: Among spironolactone-naïve patients, the change in serum potassium did not differ after 24 hours or 48 hours but was significantly greater with spironolactone treatment compared to placebo at 72 hours (0.23 ± 0.55 vs 0.03 ± 0.60 mEq/L; P = 0.042) and 96 hours (0.32 ± 0.51 vs 0.13 ± 0.72 mEq/L; P = 0.046). Potassium supplementation was similar at treatment start and at 24 hours, but spironolactone-treated patients required substantially less potassium replacement at 48 hours (24% vs 36%; P = 0.048), 72 hours (21% vs 37%; P = 0.013), and 96 hours (11% vs 38%; P < 0.001). When the treatment arms were divided into tertiles of baseline serum potassium, there were no differences in the 96-hour log N-terminal pro-B-type natriuretic peptide levels, net fluid loss, urine output, or dyspnea relief in any of the potassium groups, with no effect modification by treatment exposure. CONCLUSIONS: Spironolactone 100 mg/day for 96 hours in patients receiving intravenous loop diuresis for acute heart failure has no clear added decongestive ability but does meaningfully limit potassium wasting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
- Department of Internal Medicine, Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, CT, USA; Hospital de Cardiologia, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
- Department of Pharmacy, Lipscomb University College of Pharmacy, Nashville, TN, USA.
- Department of Internal Medicine, Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, CT, USA.
- Baylor Scott and White Research Institute, Dallas, TX, USA; Department of Medicine, University of Mississippi Medical Center, Jackson, MS, USA.
- Department of Medicine, Division of Cardiology, The CardioVascular Center, Tufts Medical Center, Boston, MA, USA.
Zitieren
APA
Natov, P. S., Ivey-Miranda, J. B., Cox, Z. L., Rao, V. S., Butler, J., Konstam, M. A., Kiernan, M. S., Kapur, N. K., & Testani, J. M. (2024). Increased Spironolactone Dosing in Acute Heart Failure Alters Potassium Homeostasis but Does not Enhance Decongestion. Journal of Cardiac Failure, 30(11), 1522-1526. https://doi.org/10.1016/j.cardfail.2024.06.008
Vancouver
Natov PS, Ivey-Miranda JB, Cox ZL, Rao VS, Butler J, Konstam MA, et al. Increased Spironolactone Dosing in Acute Heart Failure Alters Potassium Homeostasis but Does not Enhance Decongestion. Journal of Cardiac Failure. 2024;30(11):1522-1526. doi:10.1016/j.cardfail.2024.06.008
BibTeX
@article{Natov2024,
author = {Natov, Peter S and Ivey-Miranda, Juan B and Cox, Zachary L and Rao, Veena S and Butler, Javed and Konstam, Marvin A and Kiernan, Michael S and Kapur, Navin K and Testani, Jeffrey M},
title = {Increased Spironolactone Dosing in Acute Heart Failure Alters Potassium Homeostasis but Does not Enhance Decongestion},
journal = {Journal of Cardiac Failure},
year = {2024},
volume = {30},
number = {11},
pages = {1522--1526},
doi = {10.1016/j.cardfail.2024.06.008}
}
EUVIMED